Xiangbing Qi, Ph.D. - Scientists&Research - 北京科学生命Ezpay(中国)

Xiangbing Qi, Ph.D.
Associate Investigator and Director of Chemistry Center, NIBS, Beijing，China
Phone：010--80726688-8655
E-mail：qixiangbing@cjcasa.com

Education

2005-2009

Ph.D. Organic Chemistry，Department of Biochemistry，University of Texas Southwestern Medical Center at Dallas

2001-2004

M.S. Organic Chemistry, Department of Chemistry, Tongji University

1997-2001

B.S. Applied Chemistry, School of Chemistry and Chemical Engineering, University of Jinan

Professional Experience

2021-
Associate Investigator, National Institute of Biological Sciences, Beijing, China

2013-

Director of Chemistry Center, National Institute of Biological Sciences, Beijing, China

2010-2013

Postdoctoral Fellow, Organic Chemistry and Medicinal Chemistry, Department of Biochemistry，University of Texas Southwestern Medical Center at Dallas.

2009-2010

Postdoctoral Fellow, Organic Chemistry，Department of Chemistry，University of Illinois at Urbana-Champaign.

2004-2005

Research Assistant, Organic synthesis/Medicinal chemistry，Shanghai Institute of Organic Chemistry, Chinese Academy of Science.

In general，the chemistry center provides comprehensive chemical services including: bioactive small molecule synthesis, chemical purification and structure analysis, high-throughput screening (HTS) and lead compound optimization. We provide a highly effective and robust platform to conduct professional chemical services and help biological labs to solve challenging biomedical problems. Dr. Xiangbing Qi has been working on the discovery and development of novel small-molecules therapeutics for more than 15 years. The central theme of our research program focuses on the interface of synthetic methodology, natural product total synthesis and chemical biology. We bear persistent enthusiasm for the discovery of novel synthetic strategy for the activation, functionalization, and formation of Sp3C-Sp3C or Sp3C-heteroatom single bond to efficiently build bioactive 3-D small molecules; Biomimetic total synthesis of highly bioactive natural products via dearomatization/molecular arrangement cascade based on abundant natural biomass or feedstock; In close collaboration with various elaborated labs at NIBS, we are devoted to stimulating synergistic cooperation among interdisciplinary fields to identify significant biological targets, interpret their mechanism of action and facilitate biomedical research for clinically valuable small molecule discovery. Based on high-throughput screening, computer-aided drug design and medicinal chemistry, drug development within the lab is highly focused on first-in-class drug candidates to address unmet medical needs, such as the inhibition of HBV infection, circadian clock or sleep regulation and anti-cancer therapies via either small molecule induced protein degradation or molecular glue modulated protein-protein interaction.

Selected Publications

1. Huan Yan, Lei Zhang, Yang Liu, Guoliang Sun, GuangWei Xu, Zilin Song, Wenhui Li*, and Xiangbing Qi* “Potent, persistent, and selective inhibition of human NTCP-mediated HBV infection by bile acid derivatives”, J. Med. Chem., in press.

2. Chao Yang, Songlin Bai, Chao Jiang* and Xiangbing Qi*, “Asymmetric synthesis alkylbora derivatives via enantioselectiove cross-doupling of gem-Borazirconocene Alkanes”, manuscript in preparation.

3. Xiaolei Liu, Mingliang Lou, and Xiangbing Qi*, “Asymmetric Total Synthesis of (-)-Dehydrotubifoline through a dearomatization/Fischer indole strategy”， Angew. Chem. Int. Ed., in revision

4. Lu Lv, Peihao Chen, Longzhi Cao, Yamei Li, Zhi Zeng, Yue Cui, Qingcui Wu, Jiaojiao Li, Jian-Hua Wang, Meng-Qiu Dong, Xiangbing Qi* and Ting Han*, “Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation”, eLife, 2020;9:e59994, DOI: 10.7554/eLife.599942020

5. Youwei Ai, Haibing He, Peihao Chen, Bo Yan, Wenbin Zhang, Zhangcheng Ding, Dianrong Li, Jie Chen, Yan Ma, Yang Cao, Jie Zhu, Jiaojiao Li, Jinjie Ou, Shan Du, Xiaodong Wang, Jianzhang Ma, Shuanhu Gao* and Xiangbing Qi* , “An alkaloid initiates phosphodiesterase 3A–schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity”, Nature Communication, 2020, (11), 3236

6. Chao Yang, Yadong Gao, Songlin Bai, Chao Jiang* and Xiangbing Qi*, “Chemoselective Cross-coupling of gem-Borazirconocene Alkanes with Aryl Halides”, Journal of the American Chemical Society, 2020, 142, 26, 11506

7. Dapeng Ju, Wei Zhang, Jiawei Yan, Haijiao Zhao, Wei Li, Jiawen Wang, Meimei Liao, Zhancong Xu, Zhiqiang Wang, Guanshen Zhou, Long Mei, Nannan Hou, Shuhua Ying, Tao Cai, She Chen, Xiaowen Xie, Luhua Lai, Chao Tang, Noheon Park, Joseph S. Takahashi, Niu Huang, Xiangbing Qi* and Eric Erquan Zhang*, “Chemical perturbations reveal that RUVBL2 regulates the circadian phase in mammals”, Science Translational Medicine 06 May 2020: 12, Issue 542, eaba0769;

8. Yadong Gao, Chao Yang, Sonlin Bai, Xiaolei Liu, Qingcui Wu, Chao jiang*, Xiangbing Qi*, “Visible-light-induced Nickel-catalyzed Cross-coupling with Alkylzirconocenes from Unactivated Alkenes” Chem, 2020, 675.

9. Lei Zhang, Ye Zhang, Wenting Li, Xiangbing Qi*, “Total Synthesis of (-)-Alstofolinine A through a Furan Oxidation/Rearrangement and Indole Nucleophilic Cyclization Cascade” Angew. Chem. Int. Ed. 2019, 4988.

10. Aaron Nash, Xiangbing Qi, Pradip Maity, Kyle Owens, and Uttam K. Tambar*. “Development of the Vinylogous Pictet-Spengler Cyclization and Total Synthesis of (±)‐Lundurine A” Angew. Chem. Int. Ed., 2018, 57, 6888.

11. Xuekai Zhang, Gang Lu, Meng Sun, Madhu Mahankali, Yanfei Ma, Mingming Zhang, Wangde Hua, Yuting Hu, Qingbing Wang, Jinghuo Chen, Gang He, Xiangbing Qi*, Weijun Shen*, Peng Liu*, Gong Chen*，“A general strategy for synthesis of cyclophane-braced peptide macrocycles via palladium-catalysed intramolecular sp3 C-H arylation”， Nature Chemistry，2018, 540.

12. Xueyan Ma, Peixue Li, Peihao Chen, Jinhui Li, Hongling Huang, Chao Wang, Wenjing Li, Jianping Ding, Yun Zhao, Fa-Xing Yu, Xiangbing Qi*, Lei Zhang*，“Staurosporine targets the Hippo pathway to inhibit Ezpay(中国) growth” Journal of Molecular Ezpay(中国) Biology, 2018, 10, 267.

13. Yanli Wang, Yuze Sun, Ran Cao, Dan Liu, Yuting Xie, Li Li, Xiangbing Qi*, Niu Huang*， “In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery” J. Med. Chem., 2017, 60 (20), 8552.

14. Shih-Chia Tso, Mingling Lou, Wen-Jun Gui , Cheng-Yang Wu, Jacinta L. Chuang, Lorraine K. Morlock, Noelle S. Williams, R. Max Wynn, Xiangbing Qi* and David T. Chuang* “Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-targeting Pyruvate Dehydrogenase Kinase Inhibitors” J. Med. Chem., 2017, 60 (3), 1142.

15. Shih-chia Tso^*, Xiangbing Qi^*, Wen-Jun Gui, Jacinta L. Chuang, Lorraine K. Morlock, Amy L. Wallace, Kamran Ahmed, Sunil Laxman, Philippe M. Campeau, Brendan H. Lee, Susan M. Hutson, Benjamin P. Tu, Noelle S. Williams, Uttam K. Tambar, R. Max Wynna, and David T. Chuang. , “Structure-based Design and Mechanisms of Allosteric Inhibitors for Mitochondrial Branched-chain α-Ketoacid Dehydrogenase Kinase.” Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 9728. (* Equal Contribution)

16. Xiangbing Qi, Hongli Bao, Uttam K.Tambar*. “Total Synthesis of (±)-Trigonoliimine C via Oxidative Rearrangement of an Unsymmetrical Bis-Tryptamine”, J. Am. Chem. Soc. 2011, 133, 10050-10053.

17. Hongli Bao, Xiangbing Qi, Uttam K.Tambar*. “Catalytic Enantioselective [2,3]-Rearrangements of Amine N-Oxides ”, J. Am. Chem. Soc. 2011, 133, 1206.

18. Xiangbing Qi, Grant T. Rice, Manjinder S. Lall, Mark S. Plummer, M. Christina White* “Diversification of a β-lactam Pharmacophore via Allylic C–H Amination: Accelerating Effect of Lewis Acid co-catalyst”, Tetrahedron, 2010, 66, 4816.

19. Xiaotao Pu, Xiangbing Qi, Joseph. M. Ready*. “Allenes in Asymmetric Catalysis: Asymmetric Ring Opening of meso-Epoxides Catalyzed by Allene-Containing Phosphine Oxides” J. Am. Chem. Soc. 2009, 131, 10364.

20. Xiangbing Qi, Joseph. M. Ready*. “Synthesis of Cyclopentenones from Cyclopropanes and Silyl Ynol Ethers” Angew. Chem. Int. Ed. 2008, 47, 7068.

21. Xiangbing Qi, Joseph. M. Ready*. “Copper-Promoted Cycloaddition of Diazocarbonyl Compounds with Copper Acetylides” Angew. Chem. Int. Ed. 2007, 46, 3242.

Patents

1. Wenhui Li, Xiangbing Qi, Yang Liu, Zhiqiang Wang, Bo Peng, Lei Zhang，“Betulinic Acid Derivatives Inhibit Hepatitis B and D Virus and NTCP Transport”. In preparation.

2. Xiangbing Qi, Ting Han, Peihao Chen, Lu Lv, Yamei Li, Longzhi Cao, Qingcui Wu, Jiaojiao Li, “A molecular glue regulating CDK12-DDB1 interaction to trigger Cycl in K degradation” PCT/CN2020/095482

3. David T. Chuang, Shih-Chia Tso, Xiangbing Qi, Wen-Jun Gui, Cheng-Yang Wu, Jacinta L. Chuang, Uttam K. Tambar, R. Max Wynn “Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof” US20170001958A1

4. Wenhui Li, Xiangbing Qi, Huan Yan, Yang Liu, Zhiqiang Wang, Bo Peng, Lei Zhang，“Polymeric Bile Acid Derivatives Inhibit Hepatitis B and D Virus and NTCP Transport”. US20170266206A1

5. Niu Huang, Xiangbing Qi, Yanli Wang, Yuze Sun. “Kinase Inhibitors”，WO2017152842A1

6. Xiangbing Qi, Mingliang Lou, Enlong Wu, Peihao Chen, Qingcui Wu, “Dihydroxyphenyl Sulfonylisoindoline Derivatives”, WO2018095260A1

7. Erquan Zhang, Xiangbing Qi, Dapeng Ju, Haijiao Zhao, Long Mei, Zhiqiang Wang, Qingcui Wu, “Adenosine Analog and its use in Regulating the Circadian Clock” WO2018133854A1